[go: up one dir, main page]

WO2008123469A1 - Six-membered amide compound and use thereof - Google Patents

Six-membered amide compound and use thereof Download PDF

Info

Publication number
WO2008123469A1
WO2008123469A1 PCT/JP2008/056237 JP2008056237W WO2008123469A1 WO 2008123469 A1 WO2008123469 A1 WO 2008123469A1 JP 2008056237 W JP2008056237 W JP 2008056237W WO 2008123469 A1 WO2008123469 A1 WO 2008123469A1
Authority
WO
WIPO (PCT)
Prior art keywords
amide compound
membered
membered amide
compound
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056237
Other languages
French (fr)
Japanese (ja)
Inventor
Tetsuya Iida
Ikuo Mitani
Yuichi Nakagawa
Masahiro Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of WO2008123469A1 publication Critical patent/WO2008123469A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a compound having excellent SCD1 activity inhibitory action. Specifically disclosed is a compound represented by the general formula [B-0'] below, a pharmaceutically acceptable salt thereof, or a solvate thereof. [B-0'] (In the formula, the symbols are as defined in the description.)
PCT/JP2008/056237 2007-03-30 2008-03-28 Six-membered amide compound and use thereof Ceased WO2008123469A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007095639 2007-03-30
JP2007-095639 2007-03-30
US92581607P 2007-04-23 2007-04-23
US60/925,816 2007-04-23

Publications (1)

Publication Number Publication Date
WO2008123469A1 true WO2008123469A1 (en) 2008-10-16

Family

ID=39830954

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056237 Ceased WO2008123469A1 (en) 2007-03-30 2008-03-28 Six-membered amide compound and use thereof

Country Status (1)

Country Link
WO (1) WO2008123469A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011051931A (en) * 2009-09-01 2011-03-17 Sagami Chemical Research Institute 2-acylaminothiazole derivative and method for producing the same
EP2202228A4 (en) * 2007-10-15 2011-06-29 Takeda Pharmaceutical Amide compounds and use of the same
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
WO2013061297A1 (en) * 2011-10-28 2013-05-02 Pfizer Limited Pyridazine Derivatives Useful in Therapy
JP2013544806A (en) * 2010-11-01 2013-12-19 ロマーク ラボラトリース，エル．シー． Alkylsulfinyl-substituted thiazolide compounds
JP2014520886A (en) * 2011-07-18 2014-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzamides
JP2016164177A (en) * 2010-08-23 2016-09-08 シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
US9707248B2 (en) 2013-08-02 2017-07-18 Syntrix Biosystems Inc. Use of thiopyrimidinecarboxamide for treating cancer
WO2018028517A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP2018522983A (en) * 2015-07-20 2018-08-16 イリドス リミテッド Colorant compound and colorant material containing the same
CN109354580A (en) * 2018-11-21 2019-02-19 山东罗欣药业集团股份有限公司 A kind of preparation method of Doneppezil Hydrochloride
USRE47267E1 (en) 2009-02-17 2019-03-05 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
US10278970B2 (en) 2017-02-14 2019-05-07 Eli Lilly And Company Amino pyrimidine compounds useful as SSAO inhibitors
CN103450112B (en) * 2013-08-07 2019-09-13 华东理工大学 A kind of N-bridged nitrogen-containing five-membered heterocyclic compound and its preparation and application
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
JP2020524178A (en) * 2017-05-24 2020-08-13 ヨハン ヴォルフガング ゲーテ−ウニヴェルズィテート フランクフルト アム マイン Dual regulators of farnesoid X receptor and soluble epoxide hydrolase
CN113149941A (en) * 2020-01-22 2021-07-23 中国科学院上海药物研究所 Ether compound and pharmaceutical application thereof in preventing and treating diabetes and metabolic syndrome
JP2021519263A (en) * 2018-03-23 2021-08-10 ユマニティ セラピューティクス，インコーポレーテッド Compounds and their use
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US12268687B2 (en) 2019-11-13 2025-04-08 Janssen Pharmaceutica Nv Compounds and uses thereof
US12391690B2 (en) 2017-05-17 2025-08-19 Ligachem Biosciences Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034279A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
WO2006085685A1 (en) * 2005-02-09 2006-08-17 Takeda Pharmaceutical Company Limited Pyrazole compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034279A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
WO2006085685A1 (en) * 2005-02-09 2006-08-17 Takeda Pharmaceutical Company Limited Pyrazole compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIPPS G.W. ET AL.: "Aminothiazole inhibitors of HCV RNA polymerase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 1, 2005, pages 115 - 119, XP004668761 *

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202228A4 (en) * 2007-10-15 2011-06-29 Takeda Pharmaceutical Amide compounds and use of the same
US8329691B2 (en) 2007-10-15 2012-12-11 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
USRE47267E1 (en) 2009-02-17 2019-03-05 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
USRE47415E1 (en) 2009-02-17 2019-06-04 Syntrix Biosystems, Inc. Pyrimidinecarboxamides as CXCR2 modulators
JP2011051931A (en) * 2009-09-01 2011-03-17 Sagami Chemical Research Institute 2-acylaminothiazole derivative and method for producing the same
JP2016164177A (en) * 2010-08-23 2016-09-08 シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
USRE47740E1 (en) 2010-08-23 2019-11-26 Syntrix Biosystems Inc. Aminopyridinecarboxamides as CXCR2 modulators
JP2019069946A (en) * 2010-08-23 2019-05-09 シントリックス・バイオシステムズ・インコーポレイテッドＳｙｎｔｒｉｘ Ｂｉｏｓｙｓｔｅｍｓ， Ｉｎｃ． Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
USRE48547E1 (en) 2010-08-23 2021-05-11 Syntrix Biosystems Inc. Aminopyrimidinecarboxamides as CXCR2 modulators
JP2013544806A (en) * 2010-11-01 2013-12-19 ロマーク ラボラトリース，エル．シー． Alkylsulfinyl-substituted thiazolide compounds
JP2014520886A (en) * 2011-07-18 2014-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Benzamides
US9938262B2 (en) 2011-07-18 2018-04-10 Merck Patent Gmbh Benzamides
US9358250B2 (en) 2011-10-15 2016-06-07 Genentech, Inc. Methods of using SCD1 antagonists
WO2013056148A2 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
US9273011B2 (en) 2011-10-28 2016-03-01 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
CN106220572A (en) * 2011-10-28 2016-12-14 因西必泰克新有限公司 The compound of pyridyl derivatives, purposes, compositions and test kit and preparation method
CN103958481B (en) * 2011-10-28 2017-06-30 因西必泰克新有限公司 Pyridazine derivatives useful in therapy
JP2014530902A (en) * 2011-10-28 2014-11-20 インヒビタクシン リミテッド Pyridazine derivatives useful for treatment
US10016420B2 (en) 2011-10-28 2018-07-10 Inhibitaxin Limited Substituted pyridazines for the treatment of pain
CN103958481A (en) * 2011-10-28 2014-07-30 因西必泰克新有限公司 Pyridazine derivatives useful in therapy
WO2013061297A1 (en) * 2011-10-28 2013-05-02 Pfizer Limited Pyridazine Derivatives Useful in Therapy
US9707248B2 (en) 2013-08-02 2017-07-18 Syntrix Biosystems Inc. Use of thiopyrimidinecarboxamide for treating cancer
US10993953B2 (en) 2013-08-02 2021-05-04 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10130645B2 (en) 2013-08-02 2018-11-20 Syntrix Biosystems, Inc. Use of thiopyrimidinecarboxamide for treating cancer
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
CN103450112B (en) * 2013-08-07 2019-09-13 华东理工大学 A kind of N-bridged nitrogen-containing five-membered heterocyclic compound and its preparation and application
JP2018522983A (en) * 2015-07-20 2018-08-16 イリドス リミテッド Colorant compound and colorant material containing the same
JP2021091904A (en) * 2015-07-20 2021-06-17 イリドス リミテッド Colorant compound and colorant material comprising the same
US10464928B2 (en) 2016-08-12 2019-11-05 Eli Lilly And Company Amino pyrimidine SSAO inhibitors
CN114380801A (en) * 2016-08-12 2022-04-22 伊莱利利公司 Aminopyrimidine SSAO inhibitor and preparation method thereof
KR102646063B1 (en) 2016-08-12 2024-03-12 일라이 릴리 앤드 캄파니 Amino pyrimidine ssao inhibitors
KR20230008889A (en) * 2016-08-12 2023-01-16 일라이 릴리 앤드 캄파니 Amino pyrimidine ssao inhibitors
KR20190038580A (en) * 2016-08-12 2019-04-08 일라이 릴리 앤드 캄파니 Aminopyrimidine SSAO inhibitor
KR102483876B1 (en) 2016-08-12 2023-01-03 일라이 릴리 앤드 캄파니 Aminopyrimidine SSAO inhibitors
AU2017309199B2 (en) * 2016-08-12 2022-05-12 Eli Lilly And Company Amino pyrimidine SSAO inhibitors
US10287270B2 (en) 2016-08-12 2019-05-14 Eli Lilly And Company Amino pyrimidine SSAO inhibitors
US10793552B2 (en) 2016-08-12 2020-10-06 Eli Lilly And Company Amino pyrimidine ssao inhibitors
WO2018028517A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
US10973810B2 (en) 2017-01-06 2021-04-13 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
US12433880B2 (en) 2017-01-06 2025-10-07 Janssen Pharmaceutica Nv Methods for the treatment of neurological disorders
US10471060B2 (en) 2017-02-14 2019-11-12 Eli Lilly And Company Amino pyrimidine compounds useful as SSAO inhibitors
US10278970B2 (en) 2017-02-14 2019-05-07 Eli Lilly And Company Amino pyrimidine compounds useful as SSAO inhibitors
US12391690B2 (en) 2017-05-17 2025-08-19 Ligachem Biosciences Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
JP2020524178A (en) * 2017-05-24 2020-08-13 ヨハン ヴォルフガング ゲーテ−ウニヴェルズィテート フランクフルト アム マイン Dual regulators of farnesoid X receptor and soluble epoxide hydrolase
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US12275723B2 (en) 2017-10-24 2025-04-15 Janssen Pharmaceutica Nv Compounds and uses thereof
JP2024037913A (en) * 2018-03-23 2024-03-19 ユマニティ セラピューティクス，インコーポレーテッド Compounds and their uses
JP7517992B2 (en) 2018-03-23 2024-07-17 ヤンセン ファーマシューティカ エヌ．ベー． Compounds and their uses
US12180221B2 (en) 2018-03-23 2024-12-31 Janssen Pharmaceutica Nv Compounds and uses thereof
JP2021519263A (en) * 2018-03-23 2021-08-10 ユマニティ セラピューティクス，インコーポレーテッド Compounds and their use
CN109354580A (en) * 2018-11-21 2019-02-19 山东罗欣药业集团股份有限公司 A kind of preparation method of Doneppezil Hydrochloride
CN109354580B (en) * 2018-11-21 2020-08-07 山东罗欣药业集团股份有限公司 Preparation method of donepezil hydrochloride
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
US12268687B2 (en) 2019-11-13 2025-04-08 Janssen Pharmaceutica Nv Compounds and uses thereof
CN113149941A (en) * 2020-01-22 2021-07-23 中国科学院上海药物研究所 Ether compound and pharmaceutical application thereof in preventing and treating diabetes and metabolic syndrome
US11820754B2 (en) 2020-08-25 2023-11-21 Eli Lilly And Company Polymorphs of an SSAO inhibitor

Similar Documents

Publication Publication Date Title
WO2008123469A1 (en) Six-membered amide compound and use thereof
WO2008120759A1 (en) Urea compound and use thereof
WO2009048101A1 (en) Amide compound
WO2009060835A8 (en) Novel ubiquilin-binding small molecule
WO2009028655A1 (en) Heterocyclic compound and use thereof
WO2008153159A1 (en) Amine compound and pharmaceutical use thereof
WO2009028629A1 (en) Heterocyclic compound and use thereof
WO2004101528A3 (en) Isoquinoline derivatives and their use as gfat inhibitors
EP1736465A4 (en) Aniline derivatives
WO2008142055A3 (en) Antiviral agents
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
EP1889842A4 (en) Heterocyclic compound
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
EP1864665A4 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
IL190643A0 (en) Novel dihydropseudoerythromycin derivatives
WO2010066629A3 (en) Novel azaindoles
WO2008008718A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2008120744A1 (en) Five-membered cyclic amide compound and use thereof
WO2008105526A1 (en) Macrocyclic compound
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
WO2009064374A3 (en) Oral formulations of bis(thiohydrazide amides)
WO2009020137A1 (en) Aminopyrazole amide derivative
WO2008093838A1 (en) Pyridyl imidazolidine derivative having sulfamoyl group, and pharmaceutical use thereof
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739355

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08739355

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP